Written by Blake Britten
(Reuters) -Glaxosmithkline and Pfizer giants agreed to end a lawsuit claimed that the PFIZER (RSV) virus (RSV) has allegedly violating the Portal of Patents of GSK in the competing RSV LUT, according to Thursday's hunting in the state of Delu.
GSK and Pfizer said in the deposit that they will reject the case with prejudice, which means that it cannot be renovated. Companies spokesman did not immediately respond to the requests for comment and more information, including whether the case was settled.
GSK, Pfizer and Moderna developed RSV shots approved by the US Food and Drug Administration, with GSK responsibility for RSV sales in the United States. Respiratory disease usually causes cold -like symptoms, but it is also a major cause of pneumonia in young children and older adults.
GSK sued PFIZER in 2023, arguing that the company's vaccine in New York violated GSK patents related to antigen technology. GSK said in the lawsuit that Pfizer started working on the RSV program around 2013, at least seven years after the start of GSK to develop its shot.
Pfizer denied these allegations and argued the GSK patents were invalid. The London Court persuaded to nullify the Patent in the UK relevant owned by GSK in a separate case last year.
GSK has also filed a lawsuit against PFIZER for violating Patents in the United States on technology in the PFIZER Covid-19 vaccine. This issue is still ongoing.
(Participated in Blake Briton reports in Washington; edited by David Barrio and Sandra Maller)